MA33346B1 - Combinaison antitumorale comprenant l'ave8062 et le sorafenib - Google Patents

Combinaison antitumorale comprenant l'ave8062 et le sorafenib

Info

Publication number
MA33346B1
MA33346B1 MA34428A MA34428A MA33346B1 MA 33346 B1 MA33346 B1 MA 33346B1 MA 34428 A MA34428 A MA 34428A MA 34428 A MA34428 A MA 34428A MA 33346 B1 MA33346 B1 MA 33346B1
Authority
MA
Morocco
Prior art keywords
sorafenib
ave8062
antitumor combination
antitumor
formula
Prior art date
Application number
MA34428A
Other languages
Arabic (ar)
English (en)
Inventor
Brigitte Demers
Patricia Vrignaud
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA33346B1 publication Critical patent/MA33346B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention est relative à une combinaison pharmaceutique antitumorale comprenant I`VE8062 de formule (I)..et le sorafenib de formule (II).. ces deux agents antitumoraux pouvant être sous forme de base ou sous d´un sel d´un acide pharmaceutiquement acceptable.
MA34428A 2009-05-07 2010-05-06 Combinaison antitumorale comprenant l'ave8062 et le sorafenib MA33346B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0902210A FR2945210B1 (fr) 2009-05-07 2009-05-07 Combinaison antitumorale comprenant l'ave8062 et le sorafenib
PCT/FR2010/050874 WO2010128259A1 (fr) 2009-05-07 2010-05-06 Combinaison antitumorale comprenant l'ave8062 et le sorafenib

Publications (1)

Publication Number Publication Date
MA33346B1 true MA33346B1 (fr) 2012-06-01

Family

ID=41402172

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34428A MA33346B1 (fr) 2009-05-07 2010-05-06 Combinaison antitumorale comprenant l'ave8062 et le sorafenib

Country Status (27)

Country Link
US (1) US20120108641A1 (fr)
EP (1) EP2427185A1 (fr)
JP (1) JP2012526090A (fr)
KR (1) KR20120023754A (fr)
CN (1) CN102438608A (fr)
AR (1) AR076848A1 (fr)
AU (1) AU2010244254A1 (fr)
BR (1) BRPI1014197A2 (fr)
CA (1) CA2761146A1 (fr)
CL (1) CL2011002782A1 (fr)
CO (1) CO6390102A2 (fr)
CR (1) CR20110573A (fr)
DO (1) DOP2011000335A (fr)
EA (1) EA201171366A1 (fr)
EC (1) ECSP11011440A (fr)
FR (1) FR2945210B1 (fr)
IL (1) IL216133A0 (fr)
MA (1) MA33346B1 (fr)
MX (1) MX2011011767A (fr)
NI (1) NI201100191A (fr)
PE (1) PE20120323A1 (fr)
SG (1) SG175895A1 (fr)
TN (1) TN2011000551A1 (fr)
TW (1) TW201043225A (fr)
UY (1) UY32618A (fr)
WO (1) WO2010128259A1 (fr)
ZA (1) ZA201108110B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG186376A1 (en) * 2010-06-18 2013-01-30 Sanofi Sa An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
EP2481404A1 (fr) * 2010-11-15 2012-08-01 Sanofi Combinaison antitumorale comprenant de l'ombrabuline, un dérivé de taxane et un dérivé de platine
FR2968557A1 (fr) * 2010-12-09 2012-06-15 Sanofi Aventis Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab
EP2729146B1 (fr) 2011-07-08 2017-03-08 Helmholtz-Zentrum für Infektionsforschung GmbH Médicament pour le traitement du cancer du foie
FR2978663A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cetuximab, associee a la radiotherapie
FR2978662A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie
EP3107538B1 (fr) * 2014-02-18 2020-05-27 Health Research, Inc. Traitement en association du carcinome hépatocellulaire
KR102272993B1 (ko) * 2019-07-09 2021-07-06 충남대학교산학협력단 퀴니딘 유도체를 유효성분으로 함유하는 항암보조제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
BR9909393A (pt) * 1998-04-03 2000-12-26 Ajinomoto Kk Agente antitumor, uso de um derivado de estilbeno e um composto de coordenação de platina, e, processo para o tratamento ou melhoramento de um tumor
EP2298311B1 (fr) 1999-01-13 2012-05-09 Bayer HealthCare LLC Urées de diphényle à substitution omega-carboxyaryle en tant qu'inhibiteurs de la p38 kinase
EP1140840B1 (fr) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. Diphenylurees a substituants -g(v)-carboxyaryles, inhibitrices de kinase raf
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
CN1543356B (zh) * 2001-06-25 2011-09-28 味之素株式会社 抗肿瘤剂
ATE529406T1 (de) * 2002-02-11 2011-11-15 Bayer Healthcare Llc Aryl-harnstoffe als kinase inhibitoren
FR2838437B1 (fr) 2002-04-11 2004-06-04 Aventis Pharma Sa Procedes de preparation de combretastatines
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
WO2008031835A2 (fr) * 2006-09-13 2008-03-20 Novartis Ag Méthode de traitement de maladies auto-immunes à l'aide d'inhibiteurs de la voie vegf

Also Published As

Publication number Publication date
NI201100191A (es) 2012-01-16
DOP2011000335A (es) 2011-12-15
CL2011002782A1 (es) 2012-03-30
SG175895A1 (en) 2011-12-29
WO2010128259A1 (fr) 2010-11-11
BRPI1014197A2 (pt) 2016-04-26
IL216133A0 (en) 2012-01-31
TN2011000551A1 (fr) 2013-05-24
JP2012526090A (ja) 2012-10-25
UY32618A (es) 2010-12-31
CR20110573A (es) 2011-12-08
TW201043225A (en) 2010-12-16
CO6390102A2 (es) 2012-02-29
EP2427185A1 (fr) 2012-03-14
AU2010244254A1 (en) 2011-11-24
CN102438608A (zh) 2012-05-02
PE20120323A1 (es) 2012-04-17
CA2761146A1 (fr) 2010-11-11
MX2011011767A (es) 2012-02-28
KR20120023754A (ko) 2012-03-13
FR2945210B1 (fr) 2011-07-01
AR076848A1 (es) 2011-07-13
ZA201108110B (en) 2013-01-30
FR2945210A1 (fr) 2010-11-12
EA201171366A1 (ru) 2012-05-30
ECSP11011440A (es) 2011-12-30
US20120108641A1 (en) 2012-05-03

Similar Documents

Publication Publication Date Title
CY1124882T1 (el) Αναλογα 1,4-διϋποκατεστημενης πυριδαζινης και μεθοδοι για την θεραπευτικη αγωγη καταστασεων συναφων με ανεπαρκεια smn
MA29909B1 (fr) Derives de pyridazine
TN2011000659A1 (fr) Formulation pharmaceutique
EA201490489A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
DE602006012322D1 (de) Als androgen-rezeptor-modulatoren verwendbare tetrahydrocarbazol-derivate
MA32385B1 (fr) Forme posologique pharmaceutique en capsule comprenant une formulation en suspension d'un derive d'indolinone
MA34359B1 (fr) Dérivés de carbamate d'hexafluoroisopropyle, leur préparation et leur application thérapeutique
HRP20090077A2 (en) Modulators of pharmacokinetic properties of therapeutics
MA32563B1 (fr) Dabigatran pour cathétérisme cardiaque de chirurgie percutanée
CY1108690T1 (el) Υποκατεστημενες ν-αρυλοπυρρολιδινες ως επιλεκτικοι διαμορφωτες υποδοχεα ανδρογονων
DK1761528T3 (da) 5-Amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-d]pyrimidin-derivater og beslægtede forbindelser til behandling af cancer
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
EP2037739A4 (fr) Effecteurs allostériques positifs du récepteur m1 à base de quinolone à substitution benzyle
TN2011000551A1 (fr) Combinaison antitumorale comprenant l'ave8062 et le sorafenib
TW200744677A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
PA8803201A1 (es) Derivados acidos de cicloalquilamino
MA30694B1 (fr) Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
MX342898B (es) Regimen terapéutico de la sal de diclorhidrato del (r) -6-(2-(etil (4-2(etilamino) etil) bencil) amino)-4-metoxifenil)-5, 6,7,8-tetrahidronaftaleno-2-ol.
MA32639B1 (fr) [4-(5-aminométhyl-2-fluoro-phényl)-pipéridin- 1-yl]-[7-fluoro-1- (2-méthoxy-éthyl)-4-trifluorométhoxy-1h-indol-3-yl]-méthanone en tant qu'inhibiteur de la tryptase de mastocytes
MA34776B1 (fr) Nouvelle association entre le 4-(3-(cis-hexahydrocyclopenta[c] pyrrol-2(1h)-yl]propoxy) benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament
MA31430B1 (fr) Formulation a liberation prolongee de nevirapine
MX2011011490A (es) Derivados de isoxazol-tiazol como agonistas inversos del receptor de acido gamma-aminobutirico a (gaba a), para usarse en el tratamiento de trastornos cognitivos.
WO2007103869A3 (fr) Préparations pharmaceutiques liquides et pâteuses et procédés associés
TN2011000542A1 (fr) Combinaison antitumorale comprenant le cabazitaxel et la capecitabine